Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Badylak
University of Pittsburgh at Pittsburgh, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Restoure, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Ms. Lindsey Saldin is receiving stipend and scholarship support from this award, which supports her involvement in animal and bench research that is of commercial interest to Restoure. Dr. Badylak is serving as a mentor to Ms. Saldin. Dr. Badylak's conflict arises due to his interest as an inventor of intellectual property optioned to Restoure. Dr. Badylak also holds an ownership interest in the company and serves as its Chief Scientific Officer.
Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels
PROJECT NARRATIVE THE RELATION OF OUR STUDIES TO PUBLIC HEALTH: The proposed work will address a critical barrier to progress in the cancer field by introducing a novel technology: inflammatory and neoplastic extracellular matrix hydrogels, developed from decellularized inflammatory and neoplastic esophageal adenocarcinoma (EAC) tissue, to study carcinogenesis and its functional relationship to inflammation. A more faithful recapitulation of the microenvironment will identify signaling pathways and biomarkers in EAC, and may be applied to other cancers to improve tumor engineering and drug discovery.
Filed on March 05, 2018.
Tell us what you know about Stephen Badylak's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Stephen Badylak”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephen Badylak | University of Pittsburgh at Pittsburgh | Conflict of Interest | Restoure, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.